



**A. BIOGRAPHICAL INFORMATION**

Roham T. Zamanian, M.D.  
Division of Pulmonary & Critical Care Medicine  
Stanford University School of Medicine  
300 Pasteur Drive, East Pavilion, Floor 3, M/C 5236  
Palo Alto, CA 94304

**B. ACADEMIC HISTORY**

**1. Colleges and Universities Attended**

1989 – 1994	<b>Bachelor of Science</b> , Biological Sciences University of California, Irvine
1995 - 1999	<b>Doctor of Medicine</b> University of California, Irvine College of Medicine
1999 - 2002	<b>Internship and Residency, Internal Medicine</b> University of California, Irvine Medical Center (UCIMC)
2002 - 2003	<b>Pulmonary &amp; Critical Care Fellowship</b> Division of Pulmonary & Critical Care Medicine University of California, Irvine Medical Center
2003 - 2005	<b>Pulmonary &amp; Critical Care Fellowship</b> Division of Pulmonary & Critical Care Medicine Stanford University Medical Center
2004 - 2006	<b>eBay Advanced Fellowship in Pulmonary Vascular Disease</b> Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University Medical Center

**2. Board Certification**

- 2003 American Board of Internal Medicine - Internal Medicine
- 2006 American Board of Internal Medicine – Pulmonary (recertified 2017)

**C. STANFORD UNIVERSITY EMPLOYMENT HISTORY**

7/1/06 - 7/31/07	Instructor of Medicine Division of Pulmonary & Critical Care Medicine Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine
8/1/07 - 6/30/08	Acting Assistant Professor of Medicine Division of Pulmonary and Critical Care Medicine Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine
7/1/08 - 9/30/14	Assistant Professor of Medicine Division of Pulmonary and Critical Care Medicine Vera Moulton Wall Center for Pulmonary Vascular Disease

	Stanford University School of Medicine
10/1/14 - 9/30/19	Associate Professor of Medicine Division of Pulmonary and Critical Care Medicine Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine
2/1/09 - 6/30/12	Secondary Affiliation in Division of Immunology Stanford University School of Medicine
10/1/19 – 9/30/24	Associate Professor of Medicine, UML (Reappointment) Division of Pulmonary and Critical Care Medicine Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine
06/2006 - Present	Director, Adult PH Cardiac Catheterization Laboratory Adult Pulmonary Hypertension Clinical Service Division of Pulmonary & Critical Care Medicine Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine
01/2007 - Present	Director, VMWC Clinical Database Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine
10/2007 - Present	Director, Adult Pulmonary Hypertension Clinical Service Division of Pulmonary & Critical Care Medicine Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine
03/2022 - Present	Associate Director Vera Moulton Wall Center for Pulmonary Vascular Disease Stanford University School of Medicine

## **D. PUBLIC AND PROFESSIONAL SERVICE**

### **1. Society Membership & Leadership**

- Pulmonary Hypertension Association – Scientific Leadership Council. 2011- 2016
  - The PHCC Committee – Chair Task Force #2 (funding & sustainability)
  - The Insurance and Advocacy Committee (member)
- International Right Heart Failure Foundation Scientific Working Group (member). 2014
- World Symposium on Pulmonary Hypertension (Nice, France 2018)
  - Taskforce #8 member - Trials Design & New Therapies for PAH
- PHaware – member, Medical Advisory Committee (2017-present)
- Pulmonary Vascular Research Institute – Fellow
- American Thoracic Society – Pulmonary Circulation Assembly Program Committee
- American College of Chest Physicians - Fellow
- International Society for Heart and Lung Transplantation

- Vera Moulton Wall Center 2016 pre-ATS symposium organizer–“Deep Phenotyping PAH”

## **2. Editorship**

- American Thoracic Society Pulmonary Circulation – Pulmonary Hypertension Journal Club (2007-2011)
- CHEST – Pulmonary Vascular Section associate editor (2019-present)

## **3. AdHoc Reviewer**

- New England Journal of Medicine
- Lancet
- Circulation
- Pulmonary Circulation
- Journal of the American College of Cardiology
- American Journal of Respiratory & Critical Care Medicine
- European Respiratory Journal
- CHEST
- Journal of Cardiac Failure
- International Journal of Rheumatology
- Biomarkers
- Lung
- PLOS & PLOS One
- American Heart Journal

## **4. Clinical Trial Committee Memberships**

- ASCO1 – Member, Steering and Protocol Development Committees.  
Rituximab for Scleroderma Associated Pulmonary Arterial Hypertension.  
NIH/NIAID (2010-2019)
- SYMPHONY – Member, Steering Committee.  
A Study of Macitentan in Pulmonary Arterial Hypertension to Validate PAH-SYMPACT.  
Actelion (2012-2017)
- CMREF Ranolazine – Chair, Data and Safety Monitor Board.  
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes and Right Heart Function in PAH.  
Cardiovascular Medical Research Education Fund & Gilead Sciences (2013-2015)
- Pfizer #A1481324 – Member, Revatio Clinical Endpoint Adjudication Committee.  
A Multinational Multicenter Study to Assess the Effects of Oral Sildenafil on Mortality in Adults with PAH. (2014 – 2021)
- mHealth PAH – Chair, Data and Safety Monitor Board.  
A Mobile Health Intervention in Pulmonary Arterial Hypertension  
NIH/NHLBI (2017-2021)
- Actelion – Member, Steering and Protocol Development Committees.  
PRELUDE: A Multicenter Study to Assess the Effects of Oral Macitentan on Right Heart Function in Early Pulmonary Vascular Disease. (2019 – 2020)

- Gossamer Biotech – Member, Steering Committee.  
GB002 for the Treatment of Pulmonary Arterial Hypertension. (2019 – Present)
- Triaxia Health – Member, Steering Committee.  
A Multicenter Collaborative for Deep Molecular Phenotyping in PAH. (2019 – Present)
- Aria CardioVascular – Cardiac Implant for Treatment of PAH  
Chair, Data Safety Monitoring Board Member. (2021 – Present)
- Aerovate Therapeutics – AV101 for Treatment of PAH  
Member, Data Safety Monitoring Board Member (2021 – Present)
- University of Quebec – Apabetalone for Treatment of PAH  
Member, Data Safety Monitoring Board Member (2022 – Present)

## 5. Patents

- FK506 for the treatment of pulmonary hypertension – 2011 filed by Stanford.  
Edda Spiekerkoetter (primary), Marlene Rabinovitch, Phillip Beechy, Roham Zamanian

## 6. Grant Review / Study Sections

- Pulmonary VA Merit Grant Reviewer (2012)
- VA Merit Grant Pulmonary Board External Referee for William S. Middleton Memorial Veterans Hospital (2014)
- NHLBI Loan Repayment Program Reviewer (2019) - 2019/08 ZHL1 CCT-X (C1) 1
- NHLBI Loan Repayment Program Reviewer (2021) - NOT-OD-20-133
- British Heart Foundation (2021-2022) - Senior Basic Science Research Fellowship –  
FS/SBSRF/21/31016

## 7. Academic Service

- PhD Assessment Committee Member - University of Copenhagen, Denmark (08/2019)  
Candidate: Christoffer Göransson, MD, PhD  
Title: “The Role of Cardiovascular Magnetic Resonance Imaging in Assessment of Right Heart Adaptation in Pulmonary Arterial Hypertension”.

## E. FUNDING

### CLINICAL TRIALS

#### Current:

**Study:** PHANTOM. Anastrozole in Pulmonary Arterial hypertension: AIPH2

**Role:** Principal Investigator for a multi-center study

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** National Institutes of Health / University of Pennsylvania

**Dates:**

**Subjects:** Total 81, Stanford 17

**Clinicaltrial.gov #:** NCT03229499

**Study:** PHAR, The Pulmonary Hypertension Association Registry  
**Role:** Principal Investigator for a multi-center study  
**Type:** Multi-center Observational Registry / clinical trial  
**Sponsor:** Pulmonary Hypertension Association  
**Dates:**  
**Subjects:** Total 1590, Stanford 92  
**Clinicaltrial.gov #:** NCT04071327

**Study:** Open-Label, Extension Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure and Reserved Left Ventricular Ejection Fraction  
**Role:** Site PI  
**Type:** Industry-sponsored multi-center clinical trial  
**Sponsor:** Industry (TENAX Therapeutics, Inc.)  
**Dates:** 08/2019 - 07/2025  
**Subjects:** Total 27, Stanford 3  
**Clinicaltrial.gov #:** NCT03541603

**Study:** A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)  
**Role:** Site PI  
**Type:** Industry-sponsored multi-center clinical trial  
**Sponsor:** Industry (Accelaron Pharma, Inc.)  
**Dates:** 08/2022 - 08/2025  
**Subjects:** Total 27, Stanford 3  
**Clinicaltrial.gov #:** NCT03541603

**Study:** Stanford Pulmonary Hypertension Biobank  
**Role:** Principal Investigator (Director)  
**Type:** Academic Observational biobank  
**Sponsor:** Vera Moulton Wall Center for Pulmonary Vascular Disease  
**Dates:** 06/2007 – 06/2023  
**Subjects:** Total 1125  
**Clinicaltrial.gov #:** N/A

**Study:** Stanford Pulmonary Hypertension Database  
**Role:** Principal Investigator (Director)  
**Type:** Academic Observational Database  
**Sponsor:** Vera Moulton Wall Center for Pulmonary Vascular Disease  
**Dates:** 06/2003 – 06/2023  
**Subjects:** Total 1250  
**Clinicaltrial.gov #:** N/A

**Study:** Utility of Device and App-based Mobile Health Monitoring as a Tool for Evaluation of Clinical Response in PAH (DynAMITE PAH)  
**Role:** Principal Investigator  
**Type:** Single Center Clinical Trial  
**Sponsor:** Vera Moulton Wall Center for Pulmonary Vascular Disease / PHaware  
**Dates:** 06/2021 – 06/2023  
**Subjects:** Total 61

**Clinicaltrial.gov #:** NCT03893500

**Study:** A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

**Role:** Site PI

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (Gossamer Biotech)

**Dates:** 12/21 – 12/2023

**Subjects:** 4

**Clinicaltrial.gov #:** NCT04456998

**Study:** A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH

**Role:** Site PI

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (United Therapeutics, Inc.)

**Dates:** 10/2019 – 10/2022

**Subjects:** Stanford 2

**Clinicaltrial.gov #:** NCT03626688

**Past:**

**Study:** The VISION Trial - A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients with Pulmonary Arterial Hypertension (PAH) Receiving Oral Sildenafil.

**Role:** Co-PI for a multi-center Study funded by industry (PI - Ramona Doyle)

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (Actelion Pharmaceutical)

**Subjects:** Total 67, Stanford 2

**Clinicaltrial.gov #:** NCT00302211

**Study:** Effect of Pioglitazone versus Bosentan on Metabolic Profiles and Outcomes of Insulin Resistant Patients with Pulmonary Arterial Hypertension

**Role:** Senior Investigator for the overall study

**Type:** Industry-sponsored single-center clinical trial

**Sponsor:** Industry (Actelion Pharmaceutical)

**Subjects:** Stanford 2

**Clinicaltrial.gov #:** NCT00825266

**Study:** The REVEAL Registry – Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Characterization and Management

**Role:** Principal investigator for a multi-center Study funded by industry

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (Actelion Pharmaceutical)

**Subjects:** Total 3500, Stanford 52

**Clinicaltrial.gov #:** NCT00370214

**Study:** Open Label Extension of the FREEDOM-C Trial - An International, Multicenter, Randomized, Double-blind, Placebo- Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonists and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension.

**Role:** Principal investigator for a multi-center Study funded by industry

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (United Therapeutics Pharmaceutical)

**Subjects:** Total 900, Stanford 3

**Clinicaltrial.gov #:** NCT01027949

**Study:** The PROSPECT Registry – Registry to Evaluate Room Temperature Stable Epoprostenol.

**Role:** Principal investigator for a multi-center Study funded by industry

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (Actelion Pharmaceutical)

**Subjects:** Total 200, Stanford 7

**Clinicaltrial.gov #:** N/A

**Study:** CONFRONT PAH – A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadalafil) Versus Mono-therapy (Tadalafil), 2 FDA Approved Pulmonary Hypertension Medications.

**Role:** Senior Investigator for multi-center study funded by industry

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (United Therapeutics Pharmaceutical)

**Subjects:** Total 21, Stanford 11 (Goal 30)

**Clinicaltrial.gov #:** NCT01305252

**Study:** Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies (Aspire)

**Role:** Principal investigator for a multi-center study funded by industry

**Type:** Industry-sponsored multi-center clinical trial

**Sponsor:** Industry (United Therapeutics Pharmaceutical)

**Subjects:** Total 1320, Stanford 42

**Clinicaltrial.gov #:** NCT01266265

**Study:** TrANsFoRM PAH – Phase II Study of Safety, Tolerability, and Efficacy of FK-506 (Tacrolimus) in Pulmonary Arterial Hypertension.

**Role:** Co-Senior Investigator for the overall study

**Type:** University sponsored single-center clinical trial

**Sponsor:** University (Vera Moulton Wall Center & SPARK @ Stanford University)

**Subjects:** Total 24, Goal 40

**Clinicaltrial.gov #:** NCT01647945

**Study:** SYMPHONY – A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument

**Role:** Investigator & Steering Committee Member of single-center study

**Type:** Industry sponsored single-center clinical trial

**Sponsor:** Industry (Actelion Pharmaceuticals US, Inc.)

**Subjects:** Total 275  
**Clinicaltrial.gov #:** NCT01841762

**Study:** LIBERTY - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of UBEnimex in Patients with Pulmonary ARterial HYPertension (WHO Group 1)  
**Role:** Lead and Site Principal Investigator for a multi-center study  
**Type:** Industry-sponsored multi-center clinical trial  
**Sponsor:** Industry (Eiger BioPharmaceuticals, Inc.)  
**Subjects:** Total 61, Stanford 4  
**Clinicaltrial.gov #:** NCT02664558

**Study:** A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension  
**Role:** Principal investigator for a multi-center study  
**Type:** Industry sponsored multi-center clinical trial  
**Sponsor:** Industry (Gilead Sciences)  
**Subjects:** Total 151, Stanford 0  
**Clinicaltrial.gov #:** NCT02234141

**Study:** A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients with Pulmonary Arterial Hypertension (WHO Group 1)  
**Role:** Lead and Principal investigator for a multi-center study  
**Type:** Industry-sponsored multi-center clinical trial  
**Sponsor:** Industry (Eiger BioPharmaceuticals, Inc.)  
**Subjects:** Total 61, Stanford 4  
**Clinicaltrial.gov #:** NCT02736149

**Study:** Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension with a Monoclonal Antibody to CD20 (Rituximab)  
**Role:** Protocol Committee Member and Site Principal Investigator for Multicenter Clinical Trial  
**Type:** Industry-sponsored multi-center clinical trial  
**Sponsor:** Industry (National Institute of Allergy and Infectious Disease)  
**Subjects:** Total 43, Stanford 9 (Goal 60)  
**Clinicaltrial.gov #:** NCT01086540

**Study:** BEAT. A multicenter, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added-on to treprostinil, inhaled (Tyvaso®) in subjects with pulmonary arterial hypertension  
**Role:** Principal investigator for a multi-center Study  
**Type:** Industry-sponsored multi-center clinical trial  
**Sponsor:** Industry (Lung Biotechnology PBC)  
**Subjects:** Total 273, Stanford 7  
**Clinicaltrial.gov #:** NCT01908699

**Study:** OPUS. Us-Based Observational, Drug Registry of Opsumit (Macitentan) New Users in Clinical Practice.  
**Role:** Investigator & Steering Committee Member  
**Type:** Observational  
**Sponsor:** Actelion Ltd.



**Subjects:** Total nearly 2000, Stanford 27  
**Clinicaltrial.gov #:** NCT02126943

**Study:** U.S. CTEPH Registry  
**Role:** Investigator & Steering Committee Member  
**Type:** Observational [patient registry]  
**Sponsor:** Bayer Healthcare Pharmaceuticals, Inc. / University of California, San Diego  
**Subjects:** Total 750, Stanford 4  
**Clinicaltrial.gov #:** NCT02429284

**Study:** A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure and Reserved Left Ventricular Ejection Fraction (PH HFpEF)  
**Role:** Site PI  
**Type:** Industry-sponsored multi-center clinical trial  
**Sponsor:** Industry (TENAX Therapeutics, Inc.)  
**Subjects:** Total 27, Stanford 3  
**Clinicaltrial.gov #:** NCT03541603

## **GRANTS:**

### **Current:**

**Grant:** Complement Mediated Remodeling in Pulmonary Vascular Disease  
**Source:** NIH / National Heart Lung and Blood Institute  
**Dates:** 08/2020 – 06/2025  
**Role:** Co-Investigator (PI: Kurt Stenmark)

**Grant:** Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension  
**Source:** NIH / National Heart Lung and Blood Institute (R01HL159886)  
**Dates:** 07/2021 – 06/2026  
**Role:** Principle Investigator (Multi-PI: Steve Kawut, Roham Zamanian)

**Grant:** Elafin Therapy for Pulmonary Arterial Hypertension  
**Source:** NIH / National Heart Lung and Blood Institute (P01 HL108797)  
**Dates:** 09/2017 – 06/2023 (No Cost Extension)  
**Role:** Project 3 Principal Investigator (Program PI: Marlene Rabinovitch)

**Grant:** Deep Learning for Pulmonary Embolism Imaging Decision Support  
**Source:** National Institutes of Health / NLM (R01 LM012966)  
**Dates:** 09/2017 – 06/2023 (No Cost Extension)  
**Role:** Co-Principal Investigator (PI: Nigam Shah)

**Grant:** Population-level Pulmonary Embolism Outcome Prediction with Imaging and Clinical Data: A Multi-Center Study  
**Source:** National Institutes of Health (R01 HL155410)  
**Dates:** 08/2021 – 07/2025  
**Role:** Co-Principal Investigator (PI: Nigam Shah)

**Grant:** Faculty Scholar Research Mentorship Award  
**Source:** Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford  
**Dates:** 09/2013 – 09/2023  
**Role:** Principle Investigator

**Grant:** Reclassifying Pulmonary Arterial Hypertension with Machine Learned Immune Phenotypes.  
**Source:** NIH / National Heart Lung and Blood Institute (K23 HL151892)  
**Dates:** 08/2020 – 08/2025  
**Role:** Mentor (Mentee: Andrew Sweatt)

**Grant:** PAH Algorithm Validation Study  
**Source:** Johnson & Johnson  
**Dates:** 12/2020 – 12/2022 (No Cost Extension)  
**Role:** Principle Investigator

**Past:**

**Grant:** Proteomics of Inflammation, Immunity and Pulmonary Arterial Hypertension  
**Source:** National Institutes of Health / the National Heart, Lung, and Blood Institute  
**Dates:** 08/2010 – 08/2015; Completed.  
**Role:** Human Core Director, (PI: Gary Nolan)

**Grant:** Elafin Therapy for Lung Diseases  
**Source:** NIH / National Heart Lung and Blood Institute (P01 HL 108797)  
**Dates:** 08/2011 – 08/2015 (No-cost extension to 05/2018)  
**Role:** Human Core Co-Director (Program PI: Marlene Rabinovitch)

**Grant:** Stanford PAH Transplant and preparation center  
**Source:** Continuing Medical Research and Education Fund (CMREF UL1 RR024986)  
**Dates:** 04/2006 – 03/2014  
**Role:** Stanford Site Co-PI (PI: Marlene Rabinovitch)

**Grant:** iPSC Derived Endothelial Cells as Surrogates using Pulmonary Hypertension as a Prototype Disease  
**Source:** NIH / National Heart Lung and Blood Institute (U01 HL107393)  
**Dates:** 07/2011 – 06/2016.  
**Role:** Co-Investigator, (PI: Marlene Rabinovitch)

**Grant:** Using Proteomic Signature as a Tool for Early Detection and Diagnosis of Pulmonary Arterial Hypertension  
**Source:** Blue Lips Foundation  
**Dates:** 12/2016 - 09/2018  
**Role:** Principal Investigator

**Grant:** Pulmonary Hypertension Breakthrough Initiative – Stanford PAH Transplant and preparation center  
**Source:** National Institutes of Health (Prime)/ Indiana University (R24 HL123767)  
**Dates:** 04/2014 – 03/2019  
**Role:** Co-PI (PI: M Geraci; Stanford PI: M Rabinovitch)

## F. PUBLICATIONS

### Peer-Reviewed [121 published]

#### a) Peer-Reviewed Original Research Publications [95]:

1. J Sechrist, MA Nieto, **RT Zamanian**, M Bronner-Fraser. Regulative Response of the Cranial Neural Tube after Neural Fold Ablation: Spatiotemporal Nature of Neural Crest Regeneration and up-regulation of *Slug*. *Development*. 1995 121, 4103-4115. (data collection and analysis, manuscript writing and editing)
2. CI Zoumalan, **RT Zamanian**, RL Doyle, MF Marmor. ERG evaluation of daily, high-dose sildenafil usage. *Doc Ophthalmol*, 2009 Jun; 118(3):225-31. (data collection and analysis, manuscript writing and editing)
3. GS Horng, E Ashley, L Balsam, B Reitz, **RT Zamanian**. Progressive dyspnea after CABG: Complication of Retained Epicardial Pacing Wires. *Ann Thorac Surg*. 2008 Oct; 86(4):1352-4. (data collection, manuscript writing and editing)
4. **RT Zamanian**, G Hansmann, S Snook, D Lilienfeld, K Rappaport, M Rabinovitch, G Reaven, RL Doyle. Insulin Resistance in Pulmonary Arterial Hypertension. *Eur Respir J*. 2009 Feb; 33(2):318-24. (study design, data collection and analysis, manuscript writing and editing)
5. VA de Jesus Perez, F Haddad, RH Vagelos, W Fearon, J Feinstein, **RT Zamanian**. Angina associated with left main coronary artery compression in pulmonary hypertension. *J Heart Lung Transplant*. 2009 May; 28(5):527-30. (data collection and analysis, manuscript writing and editing)
6. Haddad F, **Zamanian RT**, Beraud AS, Schnittger I, Feinstein J, Peterson T, Yang P, Doyle RL, Rosenthal D. A Novel Non-Invasive Method of Estimating Pulmonary Vascular Resistance in Patients with Pulmonary Arterial Hypertension. *J Am Soc Echocardiogr* 2009; 22: 523-529. (data collection and analysis, manuscript writing and editing)
7. Chung L, Liu J, Parsons L, Hassoun PM, McGoan M, Badesch DB, Miller DP, Nicolls MR, **Zamanian RT**. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. *Chest*. 2010 Dec; 138(6):1383-94. (study design, data collection and analysis, manuscript writing and editing)
8. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, **Zamanian RT**, Rubin LJ. Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. *Chest*. 2010 Jun; 137(6 Suppl):85S-94S. (manuscript writing and editing)
9. Kudelko KT, Nadeau K, Leung AN, Liu J, Haddad F, **Zamanian RT**, De Jesus Perez V. Epoprostenol-associated pneumonitis: diagnostic use of a T-cell proliferation assay. *J Heart Lung Transplant*. 2010 Sep; 29(9):1071-5. (data collection, manuscript writing and editing)

10. Kao L, Myer P, Nguyen L, **Zamanian RT**, Chung L. Colonic ulceration as an unusual manifestation of vasculopathy in systemic sclerosis. *Rheumatology (Oxford)*. 2011 Mar; 50(3):626-8. (manuscript writing and editing)
11. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V, **Zamanian RT**, Quertermous T, Chun HJ. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. *Arterioscler Thromb Vasc Biol*. 2011 Apr; 31(4):814-20. (data collection and analysis, manuscript writing and editing)
12. Haddad F, Fuh E, Peterson T, Skhiri M, Kudelko KT, De Jesus Perez V, Winkelmayr WC, Doyle RL, Chertow GM, **Zamanian RT**. Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. *J Card Fail*. 2011 Jul; 17(7):533-9. (study design, data collection and analysis, manuscript writing and editing)
13. Hansmann G, Plouffe BD, Hatch A, von Gise A, Sallmon H, **Zamanian RT**, Murthy SK. Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension. *J Mol Med (Berl)*. 2011 Jul 7. (data collection and analysis, manuscript writing and editing)
14. Haddad F, Peterson T, Fuh E, Kudelko K, de Jesus Perez V, Skhiri M, Vagelos R, Schnittger I, Denault AY, David R, Doyle R, **Zamanian RT**. Characteristics and Outcome following Hospitalization for Acute Right Heart Failure in patients with Pulmonary Arterial Hypertension. *Circ Heart Fail*. 2011 Nov;4(6):692-9. (study design, data collection and analysis, manuscript writing and editing)
15. Ayala E, Kudelko KT, Haddad F, **Zamanian RT**, De Jesus Perez V. The Intersection of Genes and Environment: Development of Pulmonary Arterial Hypertension in a patient with Hereditary Hemorrhagic Telangiectasia and Stimulant Exposure. *Chest*. 2012 Jun; 141(6):1598-600. (manuscript writing and editing)
16. Maxwell BG, Pearl RG, Kudelko KT, **Zamanian RT**, Hill CC. Airway Management and Perioperative Decision Making in the Patient with Severe Pulmonary Hypertension Who Requires Emergency Noncardiac Surgery. *J Cardiothorac Vasc Anesth*. 2012 Oct; 26(5):940-4. (manuscript writing and editing)
17. Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, **Zamanian RT**. Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. *Am J Cardiol*. 2012 Nov 15; 110(10):1546-50. (data collection and analysis, manuscript writing and editing)
18. Barst RJ, Chung L, **Zamanian RT**, Turner M, McGoon M. Functional Class Improvement and Three-Year Survival Outcomes in Patients with Pulmonary Arterial Hypertension in the REVEAL Registry. *Chest*. 2013 Jul; 144(1):160-8. (data analysis, manuscript writing and editing)
19. Schaffer JM, Singh SK, Joyce DL, Reitz BA, Robbins RC, **Zamanian RT**, Mallidi HR. Transplantation for Idiopathic Pulmonary Artery Hypertension in the Lung Allocation Score Era. *Circulation*. 2013 Jun 25; 127(25):2503-13. (manuscript writing and editing)

20. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, **Zamanian RT**, Inayathullah M, Fridlib M, Rajadas J, Peters-Golden M, Voelkel NF, Nicolls MR. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. *Sci Transl Med*. 2013 Aug 28; 5(200):200ra117. (manuscript writing and editing)
21. Malhotra R, Paskin-Flerlage S, **Zamanian RT**, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W, Channick RN, Morrell NW, Elliott CG, Yu PB. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. *Pulm Circ*. 2013 Apr; 3(2):369-80. (manuscript writing and editing)
22. Brunner NW, Ramachandran K, Kudelko KT, Sung YK, Spiekerkoetter E, Yang PC, **Zamanian RT**, Perez Vde J. A case of recurrent pericardial constriction presenting with severe pulmonary hypertension. *Pulm Circ*. 2013 Apr; 3(2):436-9. (data collection, manuscript writing and editing)
23. Inan OT, Pandia K, Giovangrandi L, **Zamanian RT**, Kovacs GT. A preliminary study investigating the quantification of beat-to-beat in seismocardiogram signals. *Conf Proc IEEE Eng Med Biol Soc*. 2013; 2013: 7286-9. (data collection, manuscript writing and editing)
24. Haddad F, Guihaire J, Skhiri M, Denault AY, Mercier O, Al-Halabi S, Vrtovec B, Fadel E, **Zamanian RT**, Schnittger I. Septal Curvature Is Marker of Hemodynamic, Anatomical, and Electromechanical Ventricular Interdependence in Patients with Pulmonary Arterial Hypertension. *Echocardiography*. 2014 Jul; 31(6):699-707. (manuscript writing and editing)
25. Shiran H, **Zamanian RT**, McConnell MV, Liang DH, Dash R, Heidary S, Sudini NL, Wu JC, Haddad F, Yang PC. Relationship between Echocardiographic and Magnetic Resonance Derived Measures of Right Ventricular Size and Function in Patients with Pulmonary Hypertension. *J Am Soc Echocardiogr*. 2014 Apr; 27(4):405-12. (manuscript writing and editing)
26. Brunner NW, Skhiri M, Hsi A, Haddad F, **Zamanian RT**. Impact of Insulin Resistance on Parameters of Ventricular Function in Pulmonary Arterial Hypertension. *J Heart Lung Transplant*. 2014 Jul; 33(7):721-6. (study design, data collection and analysis, manuscript writing and editing)
27. de Jesus Perez VA, Yaun K, Lyuksyutova MA, Dewey F, Orcholski ME, Shuffle EM, Mathur M, Yancy L, Rojas V, Li CG, Cao A, Alastalo TP, Khazeni N, Cimprich KA, Butte AJ, Ashley E, **Zamanian RT**. Whole Exome Sequencing Reveals Topbp1 As A Novel Gene In Idiopathic Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2014 May 15; 189(10):1260-72. (study design, data collection and analysis, manuscript writing and editing)
28. Karamanian VA, Harhay M, Grant GR, Palevsky HI, Grizzle WE, **Zamanian RT**, Ihida-Stansbury K, Taichman DB, Kawut SM, Jones PL, Erythropoietin upregulation in Pulmonary Arterial Hypertension, *Pulm Circ*. 2014 Jun;4(2):269-79. (data collection and analysis, manuscript writing and editing)
29. **Zamanian RT**, Kudelko KT, Sung YK, de Jesus Perez V, Liu J, Spiekerkoetter E. Current clinical management of pulmonary arterial hypertension. *Circ Res*. 2014 Jun 20; 115(1):131-47. (manuscript writing and editing)

30. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, **Zamanian RT**. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. *Chest*. 2014 Dec; 146(6):1494-504. (data collection and analysis, manuscript writing and editing)
31. Schaffer JM, Singh SK, Reitz BA, **Zamanian RT**, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. *JAMA*. 2015 Mar 3; 313(9):936-48. (manuscript writing and editing)
32. Nickel NP, Spiekerkoetter E, Gu M, Li CG, Li H, Kaschwich M, Diebold I, Hennings JK, Kim KY, Miyagawa K, Wang L, Cao A, Sa S, Xiang X, Stockstill RW, Nicolls MR, **Zamanian RT**, Bland RD, Rabinovitch M. Elafin Reverses Pulmonary Hypertension via Caveolin-1 Dependent Bone Morphogenetic Protein Signaling. *Am J Respir Crit Care Med*. 2015 Jun 1; 191(11):1273-86. (manuscript writing and editing)
33. Haddad F, Spruijt OA, Denault AY, Mercier O, Brunner N, Furman D, Fadel E, Bogaard HJ, Schnittger I, Vrtovec B, Wu JC, de Jesus Perez V, Vonk-Noordegraaf A, **Zamanian RT**. Right Heart Score for Predicting Outcome in Idiopathic, Familial, or Drug- and Toxin-Associated Pulmonary Arterial Hypertension. *JACC Cardiovasc Imaging*. 2015 Jun; 8(6):627-38. (study design, data collection and analysis, manuscript writing and editing)
34. Brunner NW, **Zamanian RT**, Ikeno F, Mitsutake Y, Connolly AJ, Shuffle E, Yuan K, Orcholski M, Lyons J, de Jesus Perez VA. Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (*Sus scrofa domesticus*). *Comp Med*. 2015 Jun; 65(3):217-24. (data collection and analysis, manuscript writing and editing)
35. Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, **Zamanian RT**. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2015 Jul 15; 192(2):254-7. (study design, data collection and analysis, manuscript writing and editing)
36. Rhodes CJ, Im H, Cao A, Hennings JK, Wang L, Sa S, Chen PI, Nickel NP, Miyagawa K, Hopper RK, Tojais NF, Li CG, Gu M, Spiekerkoetter E, Xian Z, Chen R, Zhao M, Kaschwich M, Del Rosario PA, Bernstein D, **Zamanian RT**, Wu JC, Snyder MP, Rabinovitch M. RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2015 Aug 1; 192(3):356-66. (manuscript writing and editing)
37. Brunner NW, Haddad F, Kobayashi Y, Hsi A, Swiston JR, Gin KG, **Zamanian RT**. Prognostic utility of right atrial emptying fractions in pulmonary arterial hypertension. *Pulm Circ*. 2015 Sep; 5(3):473-80. (manuscript writing and editing)
38. Hassoun PM, **Zamanian RT**, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Houston T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2015 Nov 1; 192(9):1102-10. (data collection, manuscript writing and editing)

39. Qian J, Tian W, Jiang X, Tamosiuniene R, Sung YK, Shuffle EM, Tu AB, Valenzuela A, Jiang S, **Zamanian RT**, Fiorentino DF, Voelkel NF, Peters-Golden M, Stenmark KR, Chung L, Rabinovitch M, Nicolls MR. Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension. *Hypertension*. 2015 Dec; 66(6):1227-39. (manuscript writing and editing)
40. Maron BA, Hess E, Maddox TM, Opatowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, **Zamanian RT**, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. *Circulation*. 2016 Mar 29; 133(13):1240-8. (analysis input, manuscript writing and editing)
41. **Zamanian RT**, Levine DJ, Bourge RC, De Souza SA, Rosenzweig EB, Alnuaimat H, Burger C, Mathai SC, Leedom N, DeAngelis K, Lim A, De Marco T. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. *Pulm Circ*. 2016 Sep; 6(3):329-37 (study design, data collection and analysis, manuscript writing and editing)
42. Jivraj K, Bedayat A, Sung YK, **Zamanian RT**, Haddad F, Leung AN, Rosenberg J, Guo HH. Left Atrium Maximal Axial Cross-Sectional Area is a Specific Computed Tomographic Imaging Biomarker of World Health Organization Group 2 Pulmonary Hypertension. *J Thorac Imaging*. 2017 Mar; 32(2):121-126 (data collection, manuscript writing and editing)
43. Tian W, Rockson SG, Jian X, Kim J, Begaye A, Shuffle EM, Tu AB, Cribb M, Nepiyushchikh Z, Feroze AH, **Zamanian RT**, Dhillon GS, Voelkel NF, Peters-Golden M, Kitajewski J, Dixon JB, Nicolls MR. Leukotriene B4 Antagonism Ameliorates Experimental Lymphedema. *Sci Transl Med*. 2017 May 10; 9(389). (manuscript writing and editing)
44. Amsallem M, Boulate D, Kooreman Z, **Zamanian RT**, Fadel G, Schnittger I, Fadel E, McConnell MV, Dhillon G, Mercier O, Haddad F. Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease. *Int J Cardiovasc Imaging*. 2017 Jun; 33(6):825-835. (data collection, manuscript writing and editing)
45. Amsallem M, Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H, Mercier O, Fadel E, Schnittger I, McConnell MV, Rabinovitch M, **Zamanian RT**, Haddad F. Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension: Comparison With Validated Models. *Circ Cardiovasc Imaging*. 2017 Jun; 10(6) pii: e005771. (data collection, manuscript writing and editing)
46. Leary PJ, Kang S, Kolb TM, Maron BA, Ralph DD, Rao Y, Tedford RJ, **Zamanian RT**. What's in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. *Int J Cardiol*. 2017 Aug 1; 240:386-391. (study design, manuscript writing and editing)
47. Orcholski ME, Khurshudyan A, Shamskhov EA, Yuan K, Chen IY, Kodani SD, Morisseau C, Hammock BD, Hong EM, Alexandrova L, Alastalo TP, Berry G, **Zamanian RT**, de Jesus Perez VA. Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-

- induced pulmonary arterial hypertension. *Am J Physiol Lung Cell Mol Physiol*. 2017 Aug 1; 313(2):L252-L266. (data collection, manuscript writing and editing)
48. Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech T, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schioppa E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, **Zamanian RT**. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. *Clin Exp Rheumatol*. 2017 Sep; 106(4):106-113. (manuscript writing and editing)
  49. Amsallem M, Boulate D, Aymami M, Guihaire J, Selej M, Huo J, Denault AY, McConnell MV, Schnittger I, Fadel E, Mercier O, **Zamanian RT**, Haddad F. Load Adaptability in Patients With Pulmonary Arterial Hypertension. *Am J Cardiol*. 2017 Sep 1; 120(5): 874-882. (data collection, manuscript writing and editing)
  50. Spiekerkoetter E, Sung YK, Sudheendra D, Scott V, Del Rosario P, Bill M, Haddad F, Long-Boyle J, Hedlin H, **Zamanian RT**. Randomized Placebo-controlled Safety and Tolerability Trial of FK506 (tacrolimus) for Pulmonary Arterial Hypertension. *Euro Respir J*. 2017 Sep 11; 50(3). pii: 1602449. doi: 10.1183/13993003.02449-2016. (study design, data collection and analysis, manuscript writing and editing)
  51. **Zamanian RT**, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jordan M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, De Jesus Perez V, Kawut SM. Features and Outcomes of Methamphetamine Associated Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2017 Sep 21. doi: 10.1164/rccm.201705-0943OC (study design, data collection and analysis, manuscript writing and editing)
  52. Aviram G, Rozenbaum Z, Ziv-Baran T, Berliner S, Topilsky Y, Fleischmann D, Sung YK, **Zamanian RT**, Guo HH. Identification of Pulmonary Hypertension Caused by Left Heart Disease (World Health Organization Group 2) Based on Cardiac Chamber Volumes Derived from Chest CT Imaging. *Chest*. 2017 Oct; 152(4): 792-799. (data collection, manuscript writing and editing)
  53. Talwar A, Garcia JGN, Tsai H, Moreno M, Lahm T, **Zamanian RT**, Machado R, Kawut SM, Selej M, Mathai S, D'Anna LH, Sahni S, Rodriguez EJ, Channick R, Fagan K, Gray M, Armstrong J, Rodriguez Lopez J, de Jesus Perez V; Pulmonary Circulation Assembly. Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement. *Am J Respir Crit Care Med*. 2017 Oct 15; 196(8):e32-e47 (manuscript writing and editing)
  54. Ventetuolo CE, Hess E, Austin ED, Barón AE, Klinger JR, Lahm T, Maddox TM, Plomondon ME, Thompson L, **Zamanian RT**, Choudhary G, Maron BA. Sex-based Differences in Veterans with Pulmonary Hypertension: Results from the Veterans Affairs-Clinical Assessment Reporting and Tracking Database. *PLoS One*. 2017 Nov 9; 12(11):e0187734. doi: 10.1371/journal.pone.0187734 (manuscript writing and editing)
  55. Saito T, Miyagawa K, Chen SY, Tamosiuniene R, Wang L, Sharpe O, Samayoa E, Harada D, Moonen JAJ, Cao A, Chen PI, Hennings JK, Gu M, Li CG, Leib RD, Li D, Adams CM, Del Rosario PA, Bill M, Haddad F, Montoya JG, Robinson WH, Fantl WJ, Nolan GP, **Zamanian RT**, Nicolls MR, Chiu CY, Ariza ME, Rabinovitch M. Upregulation of Human Endogenous



- Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension. *Circulation*. 2017 Nov 14; 136(20):1920-1935. (manuscript writing and editing)
56. Sato T, Ambale-Venkatesh B, Lima JAC, Zimmerman SL, Tedford RJ, Fujii T, Hulme OL, Pullins EH, Corona-Villalobos CP, **Zamanian RT**, Minai OA, Girgis RE, Chin K, Khair R, Damico RL, Kolb TM, Mathai SC, Hassoun PM. The Impact of Ambrisentan and Tadalafil Upfront Combination Therapy on Cardiac Function in Scleroderma Associated Pulmonary Arterial Hypertension Patients: Cardiac Magnetic Resonance Feature Tracking Study. *Pulm Circ*. 2018 Jan; 8(1):2045893217748307. doi: 10.1177/2045893217748307 (data collection, manuscript writing and editing)
  57. Blum LK, Cao RRL, Sweatt AJ, Bill M, Lahey LJ, Hsi AC, Lee CS, Kongpachith S, Ju CH, Mao R, Wong HH, Nicolls MR, **Zamanian RT**, Robinson WH. Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension. *Eur J Immunol*. 2018 Jan 25. doi: 10.1002/eji.201747460. (data collection, manuscript writing and editing)
  58. Mercurio V, Mukherjee M, Tedford RJ, **Zamanian RT**, Khair RM, Sato T, Minai OA, Torres F, Girgis RE, Chin K, Damico R, Kolb TM, Mathai SC, Hassoun PM. Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2018 Feb 1; 197(3):388-391. (data collection, manuscript writing and editing)
  59. Orcholski ME, Yuan K, Rajasingh C, Tsai H, Shamskhou EA, Dhillon NK, Voelkel NF, **Zamanian RT**, de Jesus Perez VA. Drug Induced Pulmonary Arterial Hypertension: A Primer for Clinicians and Scientists. *Am J Physiol Lung Cell Mol Physiol*. 2018 Feb 8. doi: 10.1152/ajplung.00553.2017. (manuscript writing and editing)
  60. Leary PJ, Hess E, Barón AE, Branch KR, Choudhary G, Hough CL, Maron BA, Ralph DD, Ryan JJ, Tedford RJ, Weiss NS, **Zamanian RT**, Lahm T. H2-receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. *Am J Respir Crit Care Med*. 2018 Feb 13. doi: 10.1164/rccm.201801-0048LE (manuscript writing and editing)
  61. Duarte JD, Kansal M, Desai AA, Riden K, Arwood MJ, Yacob AA, Stamos TD, Cavallari LH, **Zamanian RT**, Shah SJ, Machado RF. Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. *Pulm Circ*. 2018 Apr-Jun;8(2) (sample/data collection, manuscript writing and editing)
  62. Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, **Zamanian RT**, Zastrow MS, Badesch DB. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. *Chest*. 2018 Apr 26. pii: S0012-3692(18)30649-4. doi: 10.1016/j.chest.2018.04.027. (manuscript writing and editing)
  63. Abbasi Y, Jabbari J, Jabbari R, Glinge C, Izadyar SB, Spiekerkoetter E, **Zamanian RT**, Carlsen J, Tfelt-Hansen J. Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension. *Mol Genet Genomic Med*. 2018 Aug 6. doi: 10.1002/mgg3.452. (manuscript writing and editing)
  64. French S, Amsallem M, Ouazani N, Li S, Kudelko K, **Zamanian RT**, Haddad F, Chung L. Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated

- pulmonary arterial hypertension. *Pulm Circ.* 2018 Jul-Sep;8(3): Epub 2018 Jun 25. (data collection, manuscript writing and editing)
65. Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, Bocobo GA, Tumelty KE, Faugno AJ, Tronccone L, McNeil ME, Huang X, Coser KR, Lai CSC, Upton PD, Goumans MJ, **Zamanian RT**, Elliott CG, Lee A, Zheng W, Berasi SP, Huard C, Morrell NW, Chung RT, Channick RW, Roberts KE, Yu PB. Bone Morphogenetic Protein 9 is a Mechanistic Biomarker of Portopulmonary Hypertension. *Am J Respir Crit Care Med.* 2018 Oct 12. doi: 10.1164/rccm.201807-1236OC. (sample/data collection, manuscript writing and editing)
  66. Sweatt AJ, Hedlin HK, Balasubramanian V, Hsi A, Blum LK, Robinson WH, Haddad F, Hickey PM, Condliffe R, Lawrie A, Nicolls MR, Rabinovitch M, Khatri P, **Zamanian RT**. Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. *Circ Res.* 2019 Mar 15;124(6):904-919. (study design, data collection, manuscript writing and editing)
  67. Nickel NP, de Jesus Perez VA, **Zamanian RT**, Fessel JP, Cogan JD, Hamid R, West JD, de Caestecker MP, Yang H, Austin ED. Low-grade albuminuria in pulmonary arterial hypertension. *Pulm Circ.* 2019 Apr-Jun;9(2). (manuscript writing and editing)
  68. Rajmohan D, Sung YK, Kudelko K, Perez VAJ, Haddad F, Tremmel J, Schnittger I, **Zamanian RT**, Spiekerkoetter EF. EXPRESS: Myocardial Bridge - An Unrecognized Cause of Chest Pain in Pulmonary Arterial Hypertension. *Pulm Circ.* 2019 Jun 12;10(1). (manuscript writing and editing)
  69. Banerjee I, Sofela M, Yang J, Chen JH, Shah NH, Ball R, Mushlin AI, Desai M, Bledsoe J, Amrhein T, Rubin DL, **Zamanian RT**, Lungren MP. Development and Performance of the Pulmonary Embolism Result Forecast Model (PERFORM) for Computed Tomography Clinical Decision Support. *JAMA Netw Open.* 2019 Aug 2;2(8):e198719 (study design, manuscript writing and editing)
  70. Tian W, Jiang X, Sung YK, Shuffle E, Wu TH, Kao PN, Tu AB, Dorfmueller P, Cao A, Wang L, Peng G, Kim Y, Zhang P, Chappell J, Pasupneti S, Dahms P, Maguire P, Chaib H, **Zamanian RT**, Peters-Golden M, Snyder MP, Voelkel NF, Humbert M, Rabinovitch M, Nicolls MR. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. *Circulation.* 2019 Oct 22;140(17):1409-1425 (manuscript writing and editing)
  71. Tsai H, Lee J, Hedlin H, **Zamanian RT**, de Jesus Perez VA. Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011. *ERJ Open Res.* 2019 Oct 15;5(4):00017-2019. (manuscript writing and editing)
  72. Boulate D, Amsallem M, Kuznetsova T, **Zamanian RT**, Fadel E, Mercier O, Haddad F. Echocardiographic evaluations of right ventriculo-arterial coupling in experimental and clinical pulmonary hypertension. *Physiol Rep.* 2019 Dec;7(24):e14322. (manuscript writing and editing)
  73. Huang SC, Kothari T, Banerjee I, Chute C, Ball RL, Borus N, Huang A, Patel BN, Rajpurkar P, Irvin J, Dunmon J, Bledsoe J, Shpanskaya K, Dhaliwal A, **Zamanian RT**, Ng AY, Lungren

- MP. PENet-a scalable deep-learning model for automated diagnosis of pulmonary embolism using volumetric CT imaging. *NPJ Digit Med*. 2020 Apr 24;3:61. (study design, manuscript writing and editing)
74. Nickel NP, Shamskhov EA, Razeen MA, Condon DF, Messentier Louro LA, Dubra A, Liao YJ, **Zamanian RT**, Yuan K, Perez VAJ. Anatomic, genetic and functional properties of the retinal circulation in pulmonary hypertension. *Pulm Circ*. 2020 May 4;10(2). (manuscript writing and editing)
75. DesJardin JT, Kolaitis NA, Kime N, Kronmal RA, Benza RL, Elwing JM, Lammi MR, McConnell JW, Presberg KW, Sager JS, Shlobin OA, De Marco T; **PHAR Investigators**. Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. *J Heart Lung Transplant*. 2020 May 16:S1053-2498(20)31557-6. (data collection and editing)
76. Karnes JH, Wiener HW, Schwantes-An TH, Natarajan B, Sweatt AJ, Chaturvedi A, Arora A, Batai K, Nair V, Steiner HE, Giles JB, Yu J, Hosseini M, Pauciulo MW, Lutz KA, Coleman AW, Feldman J, Vanderpool R, Tang H, Garcia JGN, Yuan JX, Kittles R, de Jesus Perez V, **Zamanian RT**, Rischard F, Tiwari HK, Nichols WC, Benza RL, Desai AA. Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2020 Jun 1;201(11):1407-1415. (manuscript writing and editing)
77. Yuan K, Liu Y, Zhang Y, Nathan A, Tian W, Yu J, Sweatt AJ, Shamskhov EA, Condon D, Chakraborty A, Agarwal S, Auer N, Zhang S, Wu JC, **Zamanian RT**, Nicolls MR, de Jesus Perez VA. Mural Cell SDF1 Signaling Is Associated with the Pathogenesis of Pulmonary Arterial Hypertension. *Am J Respir Cell Mol Biol*. 2020 Jun;62(6):747-759. (manuscript writing and editing)
78. Quantifying the Influence of Wedge Pressure, Age, and Heart Rate on the Systolic Thresholds for Detection of Pulmonary Hypertension. Amsallem M, Tedford RJ, Denault A, Sweatt AJ, Guihaire J, Hedman K, Peighambari S, Kim JB, Li X, Miller RJH, Mercier O, Fadel E, **Zamanian RT**, Haddad F. *J Am Heart Assoc*. 2020 Jun 2;9(11):e016265. (manuscript writing and editing)
79. **Zamanian RT**, Pollack CV Jr, Gentile MA, Rashid M, Fox JC, Mahaffey KW, de Jesus Perez V. Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection. *Am J Respir Crit Care Med*. 2020 Jul 1;202(1):130-132. (study design, data collection, manuscript writing and editing)
80. Lee JD, Burger CD, Delossantos GB, Grinnan D, Ralph DD, Rayner SG, Ryan JJ, Safdar Z, Ventetuolo CE, **Zamanian RT**, Leary PJ. A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with PAH or CTEPH and Impact on the Process of Care. *Ann Am Thorac Soc*. 2020 Jul 29. doi: 10.1513/AnnalsATS.202005-521OC. Epub ahead of print. (manuscript writing and editing)
81. Lahm T, Hess E, Barón AE, Maddox TM, Plomondon ME, Choudhary G, Maron BA, **Zamanian RT**, Leary PJ. Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database. *Chest*. 2021 Apr;159(4):1586-1597. doi: 10.1016 / j.chest.2020. 09. 258 Epub 2020 Oct 5. PMID: 33031831 (manuscript writing and editing)

82. Oh S, Jang AY, Chae S, Choi S, Moon J, Kim M, Spiekerkoetter E, **Zamanian RT**, Yang PC, Hwang D, Byun K, Chung WJ. Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension. *Sci Rep*. 2021 Jan 21;11(1):2012. doi: 10.1038/s41598-021-81244-1. PMID: 33479312 (manuscript writing and editing)
83. Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, **Zamanian RT**; PHAR Study Group. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. *Eur Respir J*. 2021 Feb 25;57(2):2000414. doi: 10.1183/13993003.00414-2020. Print 2021 Feb. PMID: 33243844 (study design, data collection and analysis, manuscript writing and editing)
84. **Zamanian RT**, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, Keyes-Elstein L, D'Aveta C, Szychala M, White RJ, Hassoun PM, Torres F, Sweatt AJ, Molitor JA, Khanna D, Maecker H, Welch B, Goldmuntz E, Nicolls MR; NIH ASC01 Study Group. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial. *Am J Respir Crit Care Med*. 2021 Mar 2. doi: 10.1164/rccm.202009-3481OC. Online ahead of print. PMID: 33651671 (study design, data collection and analysis, manuscript writing and editing)
85. Burkhoff D, Borlaug BA, Shah SJ, Zolty R, Tedford RJ, Thenappan T, **Zamanian RT**, Mazurek JA, Rich JD, Simon MA, Chung ES, Raza F, Majure DT, Lewis GD, Preston IR, Rich S. Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial. *JACC Heart Fail*. 2021 May;9(5):360-370. doi: 10.1016/j.jchf.2021.01.015. Epub 2021 Apr 7. PMID: 33839076 (study conduct, data collection, manuscript writing and editing)
86. Amsallem M, Sweatt AJ, Arthur Ataam J, Guihaire J, Lecerf F, Lambert M, Ghigna MR, Ali MK, Mao Y, Fadel E, Rabinovitch M, de Jesus Perez V, Spiekerkoetter E, Mercier O, Haddad F, **Zamanian RT**. Targeted proteomics of right heart adaptation to pulmonary arterial hypertension. *Eur Respir J*. 2021 Apr 8;57(4):2002428. doi: 10.1183/13993003.02428-2020. Print 2021 Apr. PMID: 33334941 (study design, data collection and analysis, manuscript writing and editing)
87. Kolaitis NA, **Zamanian RT**, de Jesus Perez VA, Badesch DB, Benza RL, Burger CD, Chakinala MM, Elwing JM, Feldman J, Lammi MR, Mathai SC, McConnell JW, Presberg KW, Robinson JC, Sager J, Shlobin OA, Simon MA, Kawut SM, Glidden DV, Singer JP, De Marco T; Pulmonary Hypertension Association Registry Investigators. Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. *Ann Am Thorac Soc*. 2021 Apr;18(4):613-622. doi: 10.1513/AnnalsATS.202007-774OC. PMID: 33064950 (study design, data collection, manuscript writing and editing)
88. Boehm M, Tian X, Ali MK, Mao Y, Ichimura K, Zhao M, Kuramoto K, Dannewitz Prosseda S, Fajardo G, Dufva MJ, Qin X, Kheyfets VO, Bernstein D, Reddy S, Metzger RJ, **Zamanian RT**, Haddad F, Spiekerkoetter E. Improving Right Ventricular Function by Increasing BMP Signaling with FK506. *Am J Respir Cell Mol Biol*. 2021 May 3. doi: 10.1165/rcmb.2020-0528OC. Online ahead of print. PMID: 33938785 (Manuscript writing and editing)

89. Montané BE, Fiore AM, Reznicek EC, Jain V, Jellis C, Rokadia H, Li M, Wang X, Dweik R, Loh E, Watkins AC, Haddad F, Amsallem M, **Zamanian RT**, Perez VJ, Heresi GA. Optimal Tricuspid Regurgitation Velocity to Screen for Pulmonary Hypertension in Tertiary Referral Centers. *Chest*. 2021 Jul 1:S0012-3692(21)01276-9. doi: 10.1016/j.chest.2021.06.046. Online ahead of print. PMID: 34217680 (Manuscript writing and editing)
90. Sweatt AJ, Miyagawa K, Rhodes CJ, Taylor S, Del Rosario PA, Hsi A, Haddad F, Spiekerkoetter E, Bental-Roof M, Bland RD, Swietlik EM, Gräf S, Wilkins MR, Morrell NW, Nicolls MR, Rabinovitch M, **Zamanian RT**. Severe Pulmonary Arterial Hypertension is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. *Chest*. 2021 Jun 25:S0012-3692(21)01255-1. doi: 10.1016/j.chest.2021.06.028. Online ahead of print. PMID: 34181952 (study design, data collection and analysis, manuscript writing and editing)
91. Haddad F, Contrepolis K, Amsallem M, Denault AY, Bernardo RJ, Jha A, Taylor S, Arthur Ataam J, Mercier O, Kouznetsova T, Vonk Noordegraaf A, **Zamanian RT**, Sweatt AJ. The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension. *Chest*. 2021 Nov 11:S0012-3692(21)04275-6. doi: 10.1016/j.chest.2021.10.045. Online ahead of print. PMID: 34774527 (study design, data collection and analysis, manuscript writing and editing)
92. Frantz RP, Benza RL, Channick RN, Chin K, Howard LS, McLaughlin VV, Sitbon O, **Zamanian RT**, Hemnes AR, Cravets M, Bruey JM, Roscigno R, Mottola D, Elman E, Zisman LS, Ghofrani HA. TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled servalutinib for the treatment of pulmonary arterial hypertension. *Pulm Circ*. 2021 Nov;11(4):20458940211057071. doi: 10.1177/20458940211057071. eCollection 2021 Oct-Dec. PMID: 34790348. (manuscript writing and editing)
93. Thomas CA, Lee J, Bernardo RJ, Anderson RJ, Glinskii V, Sung YK, Kudelko K, Hedlin H, Sweatt A, Kawut SM, Raj R, **Zamanian RT**, de Jesus Perez V. Prescription Patterns for Pulmonary Vasodilators in the Treatment of Pulmonary Hypertension Associated With Chronic Lung Diseases: Insights From a Clinician Survey. *Front Med (Lausanne)*. 2021 Dec 3;8:764815. doi: 10.3389/fmed.2021.764815. eCollection 2021. PMID: 34926507 (study design, data analysis, manuscript writing and editing)
94. Haddad F, Ataam JA, Amsallem M, Cauwenberghs N, Kuznetsova T, Rosenberg-Hasson Y, **Zamanian RT**, Karakikes I, Horne BD, Muhlestein JB, Kwee L, Shah S, Maecker H, Knight S, Knowlton K. Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study. *J Card Fail*. 2021 Dec 31:S1071-9164(21)00526-1. doi: 10.1016/j.cardfail.2021.12.012. Online ahead of print. PMID: 34979242. (study design, data analysis, manuscript writing and editing)
95. Bernardo RJ, Lu D, Ramirez RL 3rd, Hedlin H, Kawut SM, Bull T, De Marco T, Ford HJ, Grinnan D, Klinger JR, McConnell JW, Berman-Rosenzweig E, Shlobin OA, **Zamanian RT**, de Jesus Perez VA; PHAR Study Group. Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. *Ann Am Thorac Soc*. 2022 Mar 3. doi: 10.1513/AnnalsATS.202109-1051OC. Online ahead of print. PMID: 35239467. (study design, data collection and analysis, manuscript writing and editing)

**b) Other: Peer-Reviewed Commentaries, Reviews, and State-of-the Art Publications [26]:**

1. J Olsson, **RT Zamanian**. Toxicity of Local Anesthetics in the Emergency Department. *emedicine* (Emergency Medicine) Online. 2005 [www.emedicine.com](http://www.emedicine.com)
2. J Olsson, **RT Zamanian**, JA Feinstein, RL Doyle. Surgical Strategies for Management of Pulmonary Arterial Hypertension. *Semin Respir Crit Care Med*. 2005 Aug; 26(4):417-28.
3. E Ketchum, **RT Zamanian**, D Fleischmann. CT-Angiography of Pulmonary Artery Thrombi and Aneurysms in Hughes-Stovin Syndrome. *Am J Roentgenol*. 2005 Aug; 185(2):330-2.
4. **RT Zamanian**, F Haddad, RL Doyle, A Weinacker. Management Strategies for Patients with Pulmonary Hypertension in the Intensive Care Unit. *Critical Care Medicine*, 2007 Sep; 35(9):2037-50.
5. **RT Zamanian**, M Gould. Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. *Curr Opin Pulm Med*, 2008 Sep; 14(5):422-6.
6. CE Ventetuolo, RL Benza, AJ Peacock, **RT Zamanian**, DB Badesch, SM Kawut. Surrogate and combined end points in pulmonary arterial hypertension. *Proc Am Thorac Soc*. 2008 Jul 15; 5(5):617-22. (manuscript writing and editing)
7. G Hansmann, **RT Zamanian**. PPAR $\gamma$  Activation: A Novel Treatment for Pulmonary Arterial Hypertensions. *Sci Transl Med*. 2009 Dec 23;1(12):12ps14.
8. Banerjee D, Haddad F, **Zamanian RT**, Nagendran J. Right ventricular failure: a novel era of targeted therapy. *Curr Heart Fail Rep*. 2010 Dec; 7(4):202-11. (manuscript writing and editing)
9. de Jesus Perez V, Kudelko K, Snook S, **Zamanian RT**. Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead. *Int J Clin Pract Suppl*. 2011 Jan; (169):8-10.
10. Perez VA, **Zamanian RT**. Chronic thromboembolic pulmonary hypertension. *N Engl J Med*. 2011 Apr 28; 364(17):1677.
11. Haddad F, Kudelko K, Mercier O, Vrtovec B, **Zamanian RT**, de Jesus Perez V. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. *Prog Cardiovasc Dis*. 2011 Sep-Oct; 54(2):154-67. (manuscript writing and editing)
12. Perez VA, Haddad F, **Zamanian RT**. Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction. *Pulm Circ*. 2012 Apr; 2(2):163-9.
13. Waxman AB, **Zamanian RT**. Pulmonary Arterial Hypertension: New insights into the optimal role of current and emerging prostacyclin therapies. *Am J Cardiol*. 2013 Mar 4; 111(5Suppl):1A-16A.
14. Mehra MR, Park MH, Landzberg MJ, Lala A, Waxman AB; International Right Heart Failure Foundation Scientific Working Group (**Zamanian RT**). Right heart failure: toward a common language. *J Heart Lung Transplant*. 2014 Feb; 33(2):123-6 (consensus discussion, manuscript writing and editing)

15. Nickel NP, O'Leary JM, Brittain EL, Fessel JP, **Zamanian RT**, West JD, Austin ED. Kidney dysfunction in patients with pulmonary arterial hypertension. *Pulm Circ*. 2017 Mar 13; 7(1):38-54. eCollection 2017 Mar. Review. (manuscript writing and editing)
16. Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, **Zamanian RT**, Solomon MA. Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. *Am J Respir Crit Care Med*. 2018 Feb 9. doi: 10.1164/rccm.201710-2093PP. (manuscript writing and editing)
17. Taylor S, Dirir O, **Zamanian RT**, Rabinovitch M, Thompson AAR. The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. *Front Med (Lausanne)*. 2018 Aug 3;5:217. doi: 10.3389/fmed.2018.00217. eCollection 2018. Review. (manuscript writing and editing)
18. McCullough M, Kholdani C, **Zamanian RT**. Prevention of Deep Vein Thrombosis and Pulmonary Embolism in High-Risk Medical Patients. *Clin Chest Med*. 2018 Sep;39(3):483-492. doi: 10.1016/j.ccm.2018.04.002. Review. (manuscript writing and editing)
19. Ramirez RL 3rd, Perez VJ, **Zamanian RT**. Methamphetamine and the risk of pulmonary arterial hypertension. *Curr Opin Pulm Med*. 2018 Sep;24(5):416-424. doi: 10.1097/MCP.0000000000000513. (manuscript writing and editing)
20. Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, **Zamanian RT**, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. *Eur Respir J*. 2019 Jan 24;53(1):1801908. (manuscript writing and editing)
21. Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, **Zamanian RT**, de Jesus Perez VA. Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med*. 2020 Jan 15;201(2):148-157. (manuscript writing and editing)
22. Ryan JJ, Melendres-Groves L, **Zamanian RT**, Oudiz RJ, Chakinala M, Rosenzweig EB, Gomberg-Maitland M. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. *Pulm Circ*. 2020 Apr 29;10(2):2045894020920153. (manuscript writing and editing)
23. De Jesus Perez VA, **Zamanian RT**. No Good Deed Goes Unpunished: Mitomycin-Induced Pulmonary Venooclusive Disease and Cancer. *Chest*. 2021 Mar;159(3):910-911. doi: 10.1016/j.chest.2020.10.060. PMID: 33678275 (manuscript writing and editing)
24. Ramirez RL 3rd, Pienkos SM, de Jesus Perez V, **Zamanian RT**. Pulmonary Arterial Hypertension Secondary to Drugs and Toxins. *Clin Chest Med*. 2021 Mar;42(1):19-38. doi: 10.1016/j.ccm.2020.11.008. PMID: 33541612 Review. (manuscript writing and editing)
25. Oldham WM, Hemnes AR, Aldred MA, Barnard J, Brittain EL, Chan SY, Cheng F, Cho MH, Desai AA, Garcia JGN, Geraci MW, Ghiassian SD, Hall KT, Horn EM, Jain M, Kelly RS, Leopold JA, Lindstrom S, Modena BD, Nichols WC, Rhodes CJ, Sun W, Sweatt AJ, Vanderpool RR, Wilkins MR, Wilmot B, **Zamanian RT**, Fessel JP, Aggarwal NR, Loscalzo J, Xiao L. NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification:

JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021 Apr 27;77(16):2040-2052. doi: 10.1016/j.jacc.2021.02.056. PMID: 33888254 (manuscript writing and editing)

26. Condon DF, Agarwal S, Chakraborty A, Auer N, Vazquez R, Patel H, **Zamanian RT**, de Jesus Perez VA. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. *Chest*. 2021 Oct 13:S0012-3692(21)04093-9. doi: 10.1016/j.chest.2021.10.010. Online ahead of print. PMID: 34655569. (manuscript writing and editing)

### c) Non-Peer Reviewed [2 published]

1. **RT Zamanian**. Nosocomial Infections in the Intensive Care Unit. *Respiratory Therapy International*, 1996 Vol 5 (1), 87-89.
2. **RT Zamanian**. Double Lung Transplantation in Cystic Fibrosis Patients. *Respiratory Therapy International*, 1996 Vol 5 (1), 39-40.

### Books Edited & Book Chapters (5 published)

1. M Brenner, M Safani, G Heal, F Mazdisnian, R Klein, **R Zamanian**, S Gallacher, H Poggemeyer, G Foster, F Daneschvar, M Krutzik, A Wilson. Current Clinical Strategies: Manual of Critical Care Medicine. 2002-2003 Edition. CCS Publishing.
2. DV Daniels, SG Rockson, R Vagelos. Concise Cardiology: An Evidence-Based Handbook – Chapter 10: Pulmonary Hypertension. F Haddad, RL Doyle, JC Liu, **RT Zamanian**. Lippincott Williams & Wilkins 2008.
3. O Distler et al. Scleroderma – modern aspects of pathogenesis, diagnosis, and therapy. Chapter 4: PAH in Systemic Sclerosis. L Chung & **RT Zamanian**. Auflage – Bermen: UNI-MED, 2009.
4. BA Maron, **RT Zamanian**, AB Waxman. Pulmonary Hypertension – Basic Science to Clinical Medicine. Springer 2015.
5. YK Lai, RT Zamanian, K Kudelko. Manual of Clinical Anesthesiology, 2<sup>nd</sup> Edition, Chapter 48. Pulmonary Hypertension and Perioperative Management Strategies. Wolters Kluwer 2021.

### G. Lectureships and Selected Presentations

#### International

- “Role of PPAR-gamma in PAH”  
Clinical trial debate organizer  
Pulmonary Vascular Research Institute Annual Meeting, January 2009  
Mexico City, Mexico
- “Insulin Resistance in Pulmonary Arterial Hypertension”  
European Respiratory Society, September 2010  
Barcelona, Spain



- “Refining Views of Co-morbidities and Vascular Responsiveness in Pulmonary Arterial Hypertension”  
Pulmonary Vascular Medicine Grand Rounds, September 2011  
Sheffield University, UK
- “Novel Future Therapeutics in Pulmonary Arterial Hypertension”  
Asia Pacific Cardiology Conference, February 2013  
Pattaya, Thailand
- “An Update on Insulin Resistance in Pulmonary Arterial Hypertension”  
International Society for Heart & Lung Transplantation Society, April 2013  
Montreal, Canada
- “Methamphetamine Associated Pulmonary Arterial Hypertension”  
European Respiratory Society, September 2013  
Barcelona, Spain
- “Methamphetamine Associated Pulmonary Arterial Hypertension”  
Stanford CV Institute – Gachon University Collaborative, July 2014  
Incheon, Korea
- “Deep Phenotyping in PAH: The Diagnostic & Therapeutic Implications of Translational Approach to Disease”  
Toronto General Hospital, Pulmonary and Critical Care Grand Rounds, April 2015  
Toronto, Canada
- “Methamphetamine Associated Pulmonary Arterial Hypertension”  
Drug Induced Pulmonary Hypertension Symposium, June 2015  
Vienna, Austria
- “Ubenimex: A leukotriene hydrolase inhibitor for the potential treatment of PAH”  
Bayer PH Global Forum, June 2016  
Berlin, Germany
- “Is there a role for rituximab in the treatment of systemic sclerosis-associated PAH?”  
Bayer PH Global Forum, June 2016  
Berlin, Germany
- “Application of Proteomic Technology to Pulmonary Vascular Diseases”  
Stanford CV Institute – Gachon University Collaborative, July 2016  
Incheon, Korea
- “From Clinical Classification to Endo-Phenotyping: A journey through characterization of a rare disease.”  
Korean Society of Hypertension, November 2017  
Seoul, South Korea
- “Why do some drugs/trials fail?”  
World Symposium on Pulmonary Hypertension 2018 – Member on Taskforce 8 –  
Clinical trial design, February 2018

- “Steps Towards Precision Medicine in Pulmonary Arterial Hypertension”  
4<sup>th</sup> Annual Meeting of Japanese Pulmonary Circulation and Pulmonary Hypertension Society, June 2019  
Hamamatsu, Japan
- “Modern-Day Risk Stratification in Pulmonary Arterial Hypertension”  
University of Copenhagen, Rigshospitalet Division of Cardiology, Aug 2019  
Copenhagen, Denmark
- “Safety and Tolerability of Rituximab in SSc-PAH”  
European Respiratory Society International Conference, Sept 2019  
Madrid, Spain
- “Hemodynamics in PAH”  
Asociación Civil de Investigación y Desarrollo on Salud, Aug 2020  
Argentina, Virtual
- “Methamphetamine Associated Pulmonary Arterial Hypertension”  
Asociación Civil de Investigación y Desarrollo on Salud, Aug 2020  
Brazil, Virtual
- “Mild PH Should Not be Treated with PAH Therapies”  
Pulmonary Vascular Research Institute, July 2021  
Global, Virtual – Pro/Con Debate
- “The Evolving Landscape of PAH Clinical Trials”  
CardioVascular Clinical Trialists Forum Global, Oct 2021  
Global, Virtual
- “Updates on the Diagnosis and Treatment of PAH”  
Korean Society of Hypertension, Nov 2021  
Incheon, South Korea, Virtual

## **United States**

- “The New Era in Chronic Obstructive Pulmonary Disease”  
Medicine Ground Rounds, October 2004  
Doctor’s Medical Center, Modesto, CA
- “An Update on Pulmonary Arterial Hypertension”  
Medicine Ground Rounds, December 2004  
St. Luke’s Hospital, San Francisco, CA
- “Management Strategies in Pulmonary Arterial Hypertension”  
Medicine Ground Rounds, January 2005  
Highland Hospital, Oakland, CA
- “Current Research & Future Therapies for Pulmonary Arterial Hypertension”  
Pulmonary Hypertension Association - California PH Forum  
Burlingame, CA, June 2005

- “Diagnosis and Treatment of Pulmonary Arterial Hypertension”  
Medicine Grand Rounds, July 2006  
St. Rose Hospital, Hayward, CA
- “Insulin Resistance in Pulmonary Arterial Hypertension”  
Pulmonary Medicine Grand Rounds, February 2007  
University of Rochester, Rochester, NY
- “Novel Biomarkers and Disease Modifiers in Pulmonary Arterial Hypertension”  
Vascular Biology Seminar, March 2007  
National Institutes of Health, Washington DC
- “Insulin Resistance in Pulmonary Arterial Hypertension”  
Pulmonary & Critical Care Medicine Grand Rounds, June 2007  
Columbia University Medical Center, New York, NY
- “An Update on the Management of Pulmonary Arterial Hypertension”  
Medicine Grand Rounds, June 2007  
Sequoia Hospital, Redwood City, CA
- “Diagnosis and Management of Pulmonary Arterial Hypertension”  
Medicine Grand Rounds, June 2010  
Eden Medical Center, Castro Valley, CA
- Discovering Novel Biomarkers, Risk Factors, and Etiologies – A New Wave of  
Clinical Research in Pulmonary Arterial Hypertension”  
Pulmonary & Critical Care Medicine Grand Rounds, May 2010  
University of California, San Diego, CA
- “Controversies in Management of Pulmonary Arterial Hypertension”  
Medicine Grand Rounds, July 2011  
John Muir Medical Center, Concord, CA
- “Guide to Diagnosis and Treatment of Pulmonary Arterial Hypertension”  
Primary Care Medicine Grand Rounds, November 2011  
St. Joseph Medical Center, Phoenix, AZ
- “Refining Views of Co-morbidities and Vascular Responsiveness in Pulmonary Arterial  
Hypertension”  
Pulmonary & Critical Care Grand Rounds, December 2011  
Baylor College of Medicine, Houston, TX
- “New Concepts and Controversies in Pulmonary Arterial Hypertension”  
Cardiology Grand Rounds, April 2012  
Allegheny General Hospital, Pittsburgh, PA
- “Impact of Insulin Resistance in Pulmonary Hypertension”  
American Thoracic Society International Conference, May 2012  
San Francisco, CA

- “Breathing Better – Oxygen supplementation and Pulmonary Rehabilitation in PAH”  
Pulmonary Hypertension Association International Conference, June 2012  
Orlando, FL
- “Refining Views of Co-morbidities and Vascular Responsiveness in Pulmonary Arterial Hypertension”  
Pulmonary & Critical Care Grand Rounds, October 2012  
University of California, Irvine College of Medicine, Orange, CA
- “Prognostic Utility of Combined Biomarkers in PAH”  
Clinical Research Lecture Series, November 2012  
Genentech, South San Francisco, CA
- “Alterations in Glucose Metabolism and PAH”  
American Thoracic Society International Conference, May 2013  
Philadelphia, PA
- “Tacrolimus for pulmonary hypertension - approaching the disease using high throughput screening of BMPR2 mutant animal”  
Pulmonary Hypertension Drug Discovery and Development Symposium, July 2014  
US-FDA, Washington DC
- “Dual Upfront Therapy for Pulmonary Arterial Hypertension”  
National Jewish Hospital, September 2014  
Denver, CO
- “BPA is urgently Necessary for Treatment of CTEPH in USA”  
UCSD National Proceedings: CTEPH, Feb 2016  
San Diego, CA
- “Exercise is an Effective Treatment for Pulmonary Hypertension”  
University of Pennsylvania Fishman Symposium, April 2016  
Philadelphia, PA
- “Fostering Collaborations to Develop Robust Clinical Trials for Rare Diseases”  
World Orphan Drug Congress, April 2016  
Washington DC
- “All Atrial Septal Defects with Pulmonary Hypertension Should be Closed”  
Stanford CVI ACHD Symposium, March 2016  
Stanford, CA
- “Overcoming Challenges of Clinical Trials for Rare Diseases: Lessons from PAH”  
Stanford CVI- Karolinska Institute Joint Symposium, October 2016  
Stanford, CA
- “Management of Pulmonary Hypertension in Solid Organ Transplant”  
Ohio State University CTC Grand Rounds, December 2016  
Columbus, OH
- “Methamphetamine Associated Pulmonary Hypertension”

PAIRE Research Institute invited Speakership, April 2017  
Oakland, CA

- “Transplantation for PH in Era of LAS”  
International Society for Heart and Lung Transplantation, April 2017  
San Diego, CA
- “Advances in Pulmonary Hypertension”  
Dignity Health – Norton Thoracic Institute. Advanced Lung Disease & Lung Transplant Symposium, February 2018  
Phoenix, AZ
- “From Clinical Classification to Precision-Phenotyping: Envisioning Precision Medicine in Pulmonary Hypertension”  
Keynote Speaker, PHA International Conference, June 2018  
Orlando, FL
- “Features and Outcomes of Methamphetamine Associated Pulmonary Hypertension”  
University of North Carolina Pulmonary Grand Rounds, Nov 2018  
Raleigh, NC
- “Autoimmunity and Inflammation in Pulmonary Arterial Hypertension”  
North Carolina Research Triangle Pulmonary Hypertension Symposium, Nov 2018  
Durham, NC
- “Future of Clinical Trials in PAH”  
Cleveland Clinic Pulmonary Hypertension Symposium, Nov 2019  
Cleveland, OH
- “Safety and Tolerability of Rituximab in SSc-PAH”  
American Heart Association International Conference, Nov 2019  
Philadelphia, USA
- “Methamphetamine Associated Pulmonary Arterial Hypertension”  
Mid-Atlantic PH Conference, Feb 2021  
Virtual
- “Methamphetamine Associated Pulmonary Arterial Hypertension”  
UCLA-Stanford Symposium, Oct 2021  
Los Angeles, CA
- “Prescription Amphetamine-Based Stimulants and the Risk of Pulmonary Hypertension”  
Minnesota PH Consortium, June 2021  
Virtual
- “Patients with Group 2 PH are not candidates for interatrial shunts!”  
CRF THT Conference, Feb 2022  
New York, NY
- “Methamphetamine Associated Pulmonary Arterial Hypertension”  
American College of Cardiology, April 2022

Washington DC

**H. Prior and Current Mentees**

<b>Name</b>	<b>Year</b>	<b>Current Position</b>
Francois Haddad, MD	2006-2008	Assistant Clinical Professor of Medicine Division of Cardiovascular Medicine Stanford University
Kristina Kudelko, MD	2008-2009	Assistant Clinical Professor of Medicine Division of Pulmonary & Critical Care Medicine Stanford University
David Poch, MD	2009-2010	Assistant Clinical Professor of Medicine Division of Pulmonary & Critical Care Medicine University of California, San Diego
Shigeki Saito, MD	2010-2011	Assistant Professor of Medicine Division of Pulmonary & Critical Care Medicine Tulane University
Lana Melendres-Groves, MD	2011-2012	Assistant Professor of Medicine Division of Pulmonary & Critical Care Medicine University of New Mexico
Nathan Brunner, MD	2012-2013	Assistant Professor of Medicine Division of Cardiology University of British Columbia, Vancouver.
Krithika Ramachandran, MD	2012-2013	Pulmonary & Critical Care Medicine Washington
Mona Selej, MD	2013-2014	Group Medical Director Actelion Pharmaceuticals
Olga Fortenko, MD	2012-2014	Pulmonary & Critical Care Medicine Sequoia Hospital
Jennifer Hellawell, MD	2014-2015	Associate Medical Director Gilead Pharmaceuticals
Cyrus Kholdani, MD	2015-2016	Assistant Professor of Medicine Director, Pulmonary Vascular Disease Program Beth Israel Deaconess Medical Center
Richard Wells, MD	2015-2016	Assistant Professor Pulmonary and Critical care Medicine Division of Pulmonary, Critical Care and Sleep Medicine University of Mississippi Medical Center
Erin Stewart, MD, MS	2014-2018	Senior Instructor Department of Medicine/Anesthesia University of Colorado Hospital
Andrew Sweatt, MD*	2014-present	Instructor

Name	Year	Current Position
		Division of Pulmonary & Critical Care Medicine Stanford University Medical Center
Ali Khan, MD	2016-2017	Assistant Professor Department of Medicine, Division of Pulmonary and Critical Care Medicine Rush University Medical Center
Karla Cruz, MD	2017-2018	Pulmonary & Critical Care Faculty Pulmonary Hypertension Program Director Palmetto Health Medical Group University of South Carolina
Katrina Lam, MD	2017-2018	Pulmonary, Critical Care, and Pulmonary Hypertension Physician Kaiser Roseville and Sacramento
Ramon Ramirez, MD	2018 - present	Fellow Division of Pulmonary & Critical Care Medicine Stanford University Medical Center
Ryan Anderson, MD	2018 - 2020	East Bay Regional Critical Care and Pulmonary Medicine, Sutter Alta Bates in Oakland
Roberto Bernardo, MD	2019 - 2020	Assistant Professor, Medicine Division of Pulmonary & Critical Care Medicine University of Oklahoma
Erica Altschul, MD	2020 - 2021	Director of Adult Pulmonary Hypertension Northwell Health Lenox Hill Hospital
Raquel Lynn, MD	2020 - present	Fellow Division of Pulmonary & Critical Care Medicine Stanford University Medical Center
Christopher Thomas, MD	2020 - 2021	Pulmonary & Critical Care Medicine Advanced Lung Disease Program Inova Fairfax Hospital
Vlad Glinskii, MD	2020 - 2021	Kaiser Permanente, Walnut Creek Pulmonary & Critical Care Medicine
Noura Alturaif, MD	2021 – present	eBay Pulmonary Vascular Disease Fellow Division of Pulmonary & Critical Care Medicine Stanford University Medical Center

\*Primary Mentor for K23 (start date 08/2020)